| Literature DB >> 12460055 |
David Verhelst1, Matthieu Monge, Jean-Luc Meynard, Bruno Fouqueray, Béatrice Mougenot, Pierre-Marie Girard, Pierre Ronco, Jerome Rossert.
Abstract
Although nephrotoxicity of cidofovir and adefovir is well established, no renal side effects have been observed yet with tenofovir, which is the third member of this family. The authors report the case of a patient who had Fanconi syndrome, nephrogenic diabetes insipidus, and acute renal failure during treatment with tenofovir, a nucleotide reverse transcriptase inhibitor that recently has been approved by the Food and Drug Administration for treatment of patients infected with human immunodeficiency virus. Copyright 2002 by the National Kidney Foundation, Inc.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12460055 DOI: 10.1053/ajkd.2002.36924
Source DB: PubMed Journal: Am J Kidney Dis ISSN: 0272-6386 Impact factor: 8.860